76 related articles for article (PubMed ID: 29529339)
1. Could OX40 agonist antibody promote activation of the anti-tumor immune response in gastric cancer?
Martins MR; Santos RLD; Jatahy KDN; Matta MCD; Batista TP; Júnior JIC; Begnami MDFS; Torres LC
J Surg Oncol; 2018 Apr; 117(5):840-844. PubMed ID: 29529339
[TBL] [Abstract][Full Text] [Related]
2. The effect of aging on OX40 agonist-mediated cancer immunotherapy.
Ruby CE; Weinberg AD
Cancer Immunol Immunother; 2009 Dec; 58(12):1941-7. PubMed ID: 19288101
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.
Turaj AH; Cox KL; Penfold CA; French RR; Mockridge CI; Willoughby JE; Tutt AL; Griffiths J; Johnson PWM; Glennie MJ; Levy R; Cragg MS; Lim SH
Sci Rep; 2018 Feb; 8(1):2278. PubMed ID: 29396470
[TBL] [Abstract][Full Text] [Related]
4. OX40: Structure and function - What questions remain?
Willoughby J; Griffiths J; Tews I; Cragg MS
Mol Immunol; 2017 Mar; 83():13-22. PubMed ID: 28092803
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
[TBL] [Abstract][Full Text] [Related]
6. Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Griffiths J; Hussain K; Smith HL; Sanders T; Cox KL; Semmrich M; Mårtensson L; Kim J; Inzhelevskaya T; Penfold CA; Tutt AL; Mockridge CI; Chan HC; English V; French RF; Teige I; Al-Shamkhani A; Glennie MJ; Frendeus BL; Willoughby JE; Cragg MS
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428585
[TBL] [Abstract][Full Text] [Related]
7. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy.
Buchan SL; Rogel A; Al-Shamkhani A
Blood; 2018 Jan; 131(1):39-48. PubMed ID: 29118006
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells.
Cohen S; Myneni S; Batt A; Guerrero J; Brumm J; Chung S
MAbs; 2021; 13(1):1898831. PubMed ID: 33729092
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals immune cell dysfunction in the peripheral blood of patients with highly aggressive gastric cancer.
Ma R; Zhou X; Zhai X; Wang C; Hu R; Chen Y; Shi L; Fang X; Liao Y; Ma L; Jiang M; Wu J; Wang R; Chen J; Cao T; Du G; Zhao Y; Wu W; Chen H; Li S; Lian Q; Guo G; Xiao J; Hutchins AP; Yuan P
Cell Prolif; 2024 May; 57(5):e13591. PubMed ID: 38319150
[TBL] [Abstract][Full Text] [Related]
10. Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.
Redmond WL
Expert Opin Biol Ther; 2023; 23(9):901-912. PubMed ID: 37587644
[TBL] [Abstract][Full Text] [Related]
11. Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer.
Mahasongkram K; Glab-Ampai K; Kaewchim K; Saenlom T; Chulanetra M; Sookrung N; Nathalang O; Chaicumpa W
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140230
[TBL] [Abstract][Full Text] [Related]
12. Azithromycin downregulates ICOS (CD278) and OX40 (CD134) expression and mTOR activity of TCR-activated T cells to inhibit proliferation.
Ansari AW; Ahmad F; Raheed T; Jochebeth A; Mateo JMP; Abdulrahman N; Joy EF; Alam MA; Buddenkotte J; Hamoudi RA; Steinhoff M
Int Immunopharmacol; 2023 Nov; 124(Pt A):110831. PubMed ID: 37633240
[TBL] [Abstract][Full Text] [Related]
13. The Progress of T Cell Immunity Related to Prognosis in Gastric Cancer.
Wei M; Shen D; Mulmi Shrestha S; Liu J; Zhang J; Yin Y
Biomed Res Int; 2018; 2018():3201940. PubMed ID: 29682534
[TBL] [Abstract][Full Text] [Related]
14. Reversal of sepsis-induced T cell dysfunction: OX-40 to the rescue?
Sherwood ER; Williams DL
J Leukoc Biol; 2021 Apr; 109(4):689-691. PubMed ID: 32991749
[TBL] [Abstract][Full Text] [Related]
15. Adapting Ferritin, a Naturally Occurring Protein Cage, to Modulate Intrinsic Agonism of OX40.
Shatz-Binder W; Azumaya CM; Leonard B; Vuong I; Sudhamsu J; Rohou A; Liu P; Sandoval W; Bol K; Izadi S; Holder PG; Blanchette C; Perozzo R; Kelley RF; Kalia Y
Bioconjug Chem; 2024 May; 35(5):593-603. PubMed ID: 38592684
[TBL] [Abstract][Full Text] [Related]
16. WITHDRAWN: Increased levels of soluble and membrane-bound OX40 ligand in patients with acute coronary syndrome.
Yan JC; Liu DM; Wang CP; Chen GH; Ding S; Liu PJ; Du RZ
Biomed Pharmacother; 2008 Sep; ():. PubMed ID: 18848769
[No Abstract] [Full Text] [Related]
17. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
18. Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Marin-Acevedo JA; Dholaria B; Soyano AE; Knutson KL; Chumsri S; Lou Y
J Hematol Oncol; 2018 Mar; 11(1):39. PubMed ID: 29544515
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
20. OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis.
Xie K; Xu L; Wu H; Liao H; Luo L; Liao M; Gong J; Deng Y; Yuan K; Wu H; Zeng Y
Oncoimmunology; 2018; 7(4):e1404214. PubMed ID: 29632718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
